Pharmaceutical Commerce

Go in-between the pages and behind the scenes of Pharmaceutical Commerce Magazine

Episodes

Pharma Pulse: White House Eyes China Drug Restrictions, Pfizer-BioNTech Vaccine Data Strong, and Samsung Biologics Secures US Deal

September 12, 2025 • 2 mins

This episode of Pharma Pulse covers reports of a White House executive order to restrict treatments discovered in China, new data showing robust immune responses from Pfizer and BioNTech’s COVID-19 vaccine in high-risk adults, and Samsung Biologics’ latest US manufacturing deal amid tariff uncertainty.

Mark as Played

Pharma Pulse: Measles Outbreak Spurs Vaccine Mandate Debate, Trump Eyes DTC Ad Restrictions, and ICER Reviews GLP-1 Costs

September 11, 2025 • 2 mins

This episode of Pharma Pulse covers Florida’s plan to roll back school vaccine mandates amid a measles outbreak, President Trump’s renewed focus on limiting direct-to-consumer pharma advertising, and ICER’s latest cost-effectiveness analysis of GLP-1 obesity treatments semaglutide and tirzepatide.

Mark as Played

Pharma Pulse: Novartis Expands Cardiovascular Pipeline, Flu Severity Drivers Identified in Seniors, and Fixing Medication Nonadherence

September 10, 2025 • 2 mins

This episode of Pharma Pulse covers Novartis’ acquisition of Tourmaline Bio to advance its cardiovascular candidate Pacibekitug, new research uncovering biological and immunological factors driving flu severity in older adults, and strategies to address the top five reasons patients don’t take their medications.

Mark as Played

Pharma Pulse: FDA Blocks Compounded GLP-1 Ingredients, RSV Vaccination Benefits Seniors, and Pharmacies Struggle With Pricing Program

September 9, 2025 • 2 mins

This episode of Pharma Pulse covers the FDA’s decision to restrict bulk ingredients for compounded GLP-1 therapies, new evidence showing RSV vaccines improve cardiorespiratory outcomes in adults over 60, and pharmacy owners’ concerns over barriers to participating in the Medicaid Drug Price Negotiation Program.

Mark as Played

Pharma Pulse: Gilead Expands R&D Hub, WHO Adds GLP-1s to Essential Medicines List, and High-Dose Flu Vaccine Shows Heart Benefits

September 8, 2025 • 2 mins

This episode of Pharma Pulse covers Gilead’s groundbreaking on a new technical development hub to accelerate biopharma innovation, the World Health Organization’s decision to add GLP-1s to its Essential Medicines List for diabetes, and new data showing high-dose influenza vaccines reduce heart risks in older adults.

Mark as Played

Pharma Pulse: Trump Appeals Tariff Ruling, Sanofi Shares Slide on Trial Miss, and COVID-19 Alters Pneumococcal Mortality

September 5, 2025 • 2 mins

This episode of Pharma Pulse covers President Trump’s appeal to the Supreme Court to preserve pharma tariffs, Sanofi’s 10% stock drop after Amlitelimab failed in Phase III, and new research showing how the COVID-19 pandemic reshaped pneumococcal mortality trends.

Mark as Played

Pharma Pulse: Amgen Invests $600M in Innovation Hub, Novartis Collaborates With Argo, and Wegovy Tops Tirzepatide in Heart Outcomes

September 4, 2025 • 2 mins

This episode of Pharma Pulse covers Amgen’s $600 million investment in a new California R&D center, Novartis’s collaboration with Argo Biopharmaceuticals to boost its cardiovascular pipeline, and new data showing Wegovy outperforming tirzepatide in reducing major adverse cardiovascular events.

Mark as Played

Pharma Pulse: FDA Approves Sanofi’s Wayrilz, OTC Triptans Show Public Health Gains, and Biosimilar Rules Streamlined

September 3, 2025 • 2 mins

This episode of Pharma Pulse covers the FDA’s approval of Sanofi’s Wayrilz for chronic immune thrombocytopenia, evidence that prescription-to-OTC switches of triptans improve migraine care access, and new FDA guidance waiving clinical efficacy studies for most monoclonal antibody biosimilars.

Mark as Played

Pharma Pulse: Flu Vaccination Rates Improve, AI Powers RNA Therapeutics, and Statin Intolerance Spurs Self-Medication Risks

September 2, 2025 • 2 mins

This episode of Pharma Pulse covers rising influenza vaccination rates among historically underserved populations, a new Circurna–GATC Health partnership using AI to advance circular RNA therapies, and fresh research showing many statin-intolerant patients are self-medicating despite limited benefits for lowering LDL cholesterol.

Mark as Played

Pharma Pulse: Child Vaccines Show Adult Protection, Lilly Pauses Mounjaro Shipments, and FDA Rejects Lytenava Resubmission

September 1, 2025 • 2 mins

This episode of Pharma Pulse covers new evidence that childhood PCV10 vaccines indirectly protect unvaccinated adults, Eli Lilly’s pause in UK Mounjaro shipments following a major price hike, and the FDA’s Complete Response Letter to Outlook Therapeutics’ resubmission for Lytenava in wet AMD.

Mark as Played

Pharma Pulse: CDC Director Pushback, Persistent Drug Shortages, and FDA Clears First Generic GLP-1 for Weight Loss

August 29, 2025 • 2 mins

This episode of Pharma Pulse covers Susan Monarez’s rejection of White House efforts to remove her as CDC director, new analysis on how long-lasting drug shortages expose systemic supply chain weaknesses, and the FDA’s approval of the first generic liraglutide for weight management.

Mark as Played

Pharma Pulse: ACOG Reaffirms COVID-19 Vaccine in Pregnancy, SGLT2 Real-World Safety Data, and EVERSANA–Waltz Tackle Drug Costs

August 28, 2025 • 2 mins

This episode of Pharma Pulse covers ACOG’s renewed support for COVID-19 vaccination during pregnancy, new real-world evidence confirming the safety of dapagliflozin and empagliflozin for type 2 diabetes, and a partnership between EVERSANA and Waltz Health to improve affordability and patient access.

Mark as Played

Pharma Pulse: FDA Boosts Transparency, CDC Appoints mRNA Critic, and Genentech Invests $700M in US Manufacturing

August 27, 2025 • 2 mins

This episode of Pharma Pulse covers the FDA’s new daily adverse event reporting initiative, the CDC’s appointment of an mRNA vaccine critic to lead its COVID-19 immunization workgroup, and Genentech’s $700 million investment in a North Carolina biologics facility.

Mark as Played

Pharma Pulse: Novo Nordisk Plant Faces FDA Scrutiny, Off-Label GLP-1 Use Grows, and AbbVie Expands Psychiatry Pipeline

August 26, 2025 • 2 mins

This episode of Pharma Pulse covers FDA findings of contamination and safety lapses at Novo’s Bloomington manufacturing plant, the rise of off-label GLP-1 prescribing and its equity challenges, and AbbVie’s acquisition of bretisilocin to advance treatments for major depressive disorder.

Mark as Played

Pharma Pulse: CVS Caremark Faces $290M Penalty, Small Practices Miss HIPAA Standards, and Pharmacists Underreport Adverse Drug Reactions

August 25, 2025 • 2 mins

This episode of Pharma Pulse covers a $290 million False Claims Act ruling against CVS Caremark, a new report showing most small medical practices fall short on HIPAA compliance, and research revealing why pharmacists underreport adverse drug reactions.

Mark as Played

Pharma Pulse: Pharma Tariffs Take Shape, J&J Invests $2 Billion in US Manufacturing, and New EHR Rule Targets Prior Authorization

August 22, 2025 • 2 mins

This episode of Pharma Pulse covers the White House–EU agreement on pharmaceutical tariffs, Johnson & Johnson’s $2 billion expansion of its North Carolina manufacturing site, and a new federal rule requiring e-prescribing and prior authorization tools in certified EHR systems.

Mark as Played

Pharma Pulse: Catalent Layoffs, Diabetes Tech Adoption, and Long-Term Heart Risks from Childhood COVID-19

August 21, 2025 • 2 mins

This episode of Pharma Pulse covers Catalent’s decision to cut 350 jobs at its Baltimore gene therapy site, new data showing rising adoption of digital tools for glycemic control in type 1 diabetes, and research linking severe childhood COVID-19 to heightened cardiovascular risk later in life.

Mark as Played

Pharma Pulse: Agile Drug Manufacturing Advances, Merck–Skyhawk RNA Deal, and Telehealth Expands Pharmacists’ Role

August 20, 2025 • 2 mins

This episode of Pharma Pulse explores a Battelle–Aprecia partnership with HHS and DARPA to accelerate on-demand drug manufacturing, a multi-billion-dollar Merck KGaA–Skyhawk collaboration to advance RNA therapies in neurology, and how pharmacist-led telehealth is improving diabetes care during emergencies.

Mark as Played

Pharma Pulse: Wegovy Wins Accelerated Approval, New Flu Combo Emerges, and Community Pharmacies Expand Access

August 19, 2025 • 2 mins

This episode of Pharma Pulse covers Novo Nordisk’s FDA win for Wegovy in MASH-related liver fibrosis, new research on a promising drug combination against resistant influenza strains, and how community pharmacies are strengthening healthcare access in underserved areas.

Mark as Played

Pharma Pulse: GLP-1 Access Partnership, Pfizer’s Sickle Cell Setback, and Patient Portal Trade-Offs

August 18, 2025 • 2 mins

This episode of Pharma Pulse covers a new collaboration to expand access to GLP-1 therapies via LillyDirect, Pfizer’s Phase III miss in sickle cell disease, and how patient portals are improving access to care while creating new workload challenges for providers.

Mark as Played

Popular Podcasts

24/7 News: The Latest

The latest news in 4 minutes updated every hour, every day.

Dateline NBC

Current and classic episodes, featuring compelling true-crime mysteries, powerful documentaries and in-depth investigations. Follow now to get the latest episodes of Dateline NBC completely free, or subscribe to Dateline Premium for ad-free listening and exclusive bonus content: DatelinePremium.com

The Clay Travis and Buck Sexton Show

The Clay Travis and Buck Sexton Show. Clay Travis and Buck Sexton tackle the biggest stories in news, politics and current events with intelligence and humor. From the border crisis, to the madness of cancel culture and far-left missteps, Clay and Buck guide listeners through the latest headlines and hot topics with fun and entertaining conversations and opinions.

Stuff You Should Know

If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.

The Charlie Kirk Show

Charlie is America's hardest working grassroots activist who has your inside scoop on the biggest news of the day and what's really going on behind the headlines. The founder of Turning Point USA and one of social media's most engaged personalities, Charlie is on the front lines of America’s culture war, mobilizing hundreds of thousands of students on over 3,500 college and high school campuses across the country, bringing you your daily dose of clarity in a sea of chaos all from his signature no-holds-barred, unapologetically conservative, freedom-loving point of view. You can also watch Charlie Kirk on Salem News Channel

Advertise With Us

Pharmaceutical Commerce

Episodes

.css-14f5ked{margin:0;word-break:break-word;display:-webkit-box;-webkit-box-orient:vertical;box-orient:vertical;-webkit-line-clamp:2;overflow:hidden;}Pharma Pulse: White House Eyes China Drug Restrictions, Pfizer-BioNTech Vaccine Data Strong, and Samsung Biologics Secures US Deal

.css-r6mb8g{margin:0;word-break:break-word;display:-webkit-box;-webkit-box-orient:vertical;box-orient:vertical;-webkit-line-clamp:1;overflow:hidden;}Pharma Pulse: Measles Outbreak Spurs Vaccine Mandate Debate, Trump Eyes DTC Ad Restrictions, and ICER Reviews GLP-1 Costs

Pharma Pulse: Novartis Expands Cardiovascular Pipeline, Flu Severity Drivers Identified in Seniors, and Fixing Medication Nonadherence

Pharma Pulse: FDA Blocks Compounded GLP-1 Ingredients, RSV Vaccination Benefits Seniors, and Pharmacies Struggle With Pricing Program

Pharma Pulse: Gilead Expands R&D Hub, WHO Adds GLP-1s to Essential Medicines List, and High-Dose Flu Vaccine Shows Heart Benefits

Pharma Pulse: Trump Appeals Tariff Ruling, Sanofi Shares Slide on Trial Miss, and COVID-19 Alters Pneumococcal Mortality

Pharma Pulse: Amgen Invests $600M in Innovation Hub, Novartis Collaborates With Argo, and Wegovy Tops Tirzepatide in Heart Outcomes

Pharma Pulse: FDA Approves Sanofi’s Wayrilz, OTC Triptans Show Public Health Gains, and Biosimilar Rules Streamlined

Pharma Pulse: Flu Vaccination Rates Improve, AI Powers RNA Therapeutics, and Statin Intolerance Spurs Self-Medication Risks

Pharma Pulse: Child Vaccines Show Adult Protection, Lilly Pauses Mounjaro Shipments, and FDA Rejects Lytenava Resubmission

Pharma Pulse: CDC Director Pushback, Persistent Drug Shortages, and FDA Clears First Generic GLP-1 for Weight Loss

Pharma Pulse: ACOG Reaffirms COVID-19 Vaccine in Pregnancy, SGLT2 Real-World Safety Data, and EVERSANA–Waltz Tackle Drug Costs

Pharma Pulse: FDA Boosts Transparency, CDC Appoints mRNA Critic, and Genentech Invests $700M in US Manufacturing

Pharma Pulse: Novo Nordisk Plant Faces FDA Scrutiny, Off-Label GLP-1 Use Grows, and AbbVie Expands Psychiatry Pipeline

Pharma Pulse: CVS Caremark Faces $290M Penalty, Small Practices Miss HIPAA Standards, and Pharmacists Underreport Adverse Drug Reactions

Pharma Pulse: Pharma Tariffs Take Shape, J&J Invests $2 Billion in US Manufacturing, and New EHR Rule Targets Prior Authorization

Pharma Pulse: Catalent Layoffs, Diabetes Tech Adoption, and Long-Term Heart Risks from Childhood COVID-19

Pharma Pulse: Agile Drug Manufacturing Advances, Merck–Skyhawk RNA Deal, and Telehealth Expands Pharmacists’ Role

Pharma Pulse: Wegovy Wins Accelerated Approval, New Flu Combo Emerges, and Community Pharmacies Expand Access

Pharma Pulse: GLP-1 Access Partnership, Pfizer’s Sickle Cell Setback, and Patient Portal Trade-Offs

Popular Podcasts

Pharma Pulse: White House Eyes China Drug Restrictions, Pfizer-BioNTech Vaccine Data Strong, and Samsung Biologics Secures US Deal

Pharma Pulse: Measles Outbreak Spurs Vaccine Mandate Debate, Trump Eyes DTC Ad Restrictions, and ICER Reviews GLP-1 Costs